Accepted Article Preview: Published ahead of advance online publication

[1]  Richard W. Foltin,et al.  Predictors of Marijuana Relapse in the Human Laboratory: Robust Impact of Tobacco Cigarette Smoking Status , 2013, Biological Psychiatry.

[2]  S. Goldberg,et al.  The opioid antagonist naltrexone reduces the reinforcing effects of Δ9-tetrahydrocannabinol (THC) in squirrel monkeys , 2004, Psychopharmacology.

[3]  B. Rounsaville,et al.  Naltrexone and coping skills therapy for alcohol dependence. A controlled study. , 1992, Archives of general psychiatry.

[4]  Rajita Sinha,et al.  Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo–pituitary–adrenocortical axis , 2002, Psychopharmacology.

[5]  K. Fujioka,et al.  Naltrexone for the treatment of obesity: review and update , 2009, Expert opinion on pharmacotherapy.

[6]  S. Galea,et al.  Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. , 2012, Drug and alcohol dependence.

[7]  Richard W. Foltin,et al.  Abstinence symptoms following smoked marijuana in humans , 1999, Psychopharmacology.

[8]  J. Franck,et al.  Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. , 2008, The American journal of psychiatry.

[9]  R. Spealman,et al.  Controversies in translational research: drug self-administration , 2008, Psychopharmacology.

[10]  N. Petry,et al.  Abstinence rates following behavioral treatments for marijuana dependence. , 2007, Addictive behaviors.

[11]  William W Stoops,et al.  Agonist replacement for stimulant dependence: a review of clinical research. , 2013, Current pharmaceutical design.

[12]  S. Goldberg,et al.  Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats , 2005, Psychopharmacology.

[13]  D. Couper,et al.  Dose-Ranging Kinetics and Behavioral Pharmacology of Naltrexone and Acamprosate, Both Alone and Combined, in Alcohol-Dependent Subjects , 2003, Journal of clinical psychopharmacology.

[14]  David Couper,et al.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. , 2006, JAMA.

[15]  S. Heishman,et al.  Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. , 2001, Archives of general psychiatry.

[16]  S. Wachtel,et al.  Naltrexone does not block the subjective effects of oral Δ9-tetrahydrocannabinol in humans , 2000 .

[17]  M. Haney.  Self‐administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls , 2009, Addiction biology.

[18]  K. Wesnes,et al.  A Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Acamprosate and Naltrexone , 2002, Neuropsychopharmacology.

[19]  M. Stitzer,et al.  The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. , 2013, Drug and alcohol dependence.

[20]  J. Volavka,et al.  Naltrexone: Disposition, metabolism, and effects after acute and chronic dosing , 1976, Clinical pharmacology and therapeutics.

[21]  E. V. Bockstaele,et al.  Cannabinoid and opioid interactions: Implications for opiate dependence and withdrawal , 2013, Neuroscience.

[22]  A. Alterman,et al.  Naltrexone in the treatment of alcohol dependence. , 1992, Archives of general psychiatry.

[23]  S. Vosburg,et al.  Marijuana Withdrawal in Humans: Effects of Oral THC or Divalproex , 2004, Neuropsychopharmacology.

[24]  M. Pavlicova,et al.  Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. , 2011, Drug and alcohol dependence.

[25]  M. Zvolensky,et al.  Cannabis use during a voluntary quit attempt: an analysis from ecological momentary assessment. , 2013, Drug and alcohol dependence.

[26]  M. Greenwald,et al.  Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. , 2000, Drug and alcohol dependence.

[27]  M. Haney,et al.  Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor , 2008, Addiction biology.

[28]  H. Kranzler,et al.  Adverse effects of oral naltrexone: analysis of data from two clinical trials , 2001, Psychopharmacology.

[29]  S. Heishman,et al.  Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users , 2007, Psychopharmacology.

[30]  M. Haney,et al.  Opioid antagonism enhances marijuana's effects in heavy marijuana smokers , 2010, Psychopharmacology.

[31]  A. Weinstein,et al.  Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study , 2014, The American journal of drug and alcohol abuse.

[32]  J. Volpicelli,et al.  Improving Naltrexone Response , 2000, Journal of addictive diseases.

[33]  R. Stephens,et al.  Abstinence and moderate use goals in the treatment of marijuana dependence. , 2006, Addiction.

[34]  G. Bedi,et al.  Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study , 2010, Psychopharmacology.

[35]  S. Vosburg,et al.  Reinforcing effects of oral Δ9-THC in male marijuana smokers in a laboratory choice procedure , 2005, Psychopharmacology.

[36]  M. Haney.  Opioid Antagonism of Cannabinoid Effects: Differences between Marijuana Smokers and Nonmarijuana Smokers , 2007, Neuropsychopharmacology.

[37]  C. S. Emurian,et al.  Effects of smoked marijuana on social interaction in small groups. , 1987, Drug and alcohol dependence.

[38]  S. Higgins,et al.  Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. , 2006, Journal of consulting and clinical psychology.

[39]  R. Griffiths,et al.  Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. , 1994, The Journal of pharmacology and experimental therapeutics.

[40]  M. Haney,et al.  Interaction between naltrexone and oral THC in heavy marijuana smokers , 2003, Psychopharmacology.

[41]  G. Koob,et al.  Functional Interaction between Opioid and Cannabinoid Receptors in Drug Self-Administration , 2001, The Journal of Neuroscience.

[42]  Lakshmi A Devi,et al.  μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis , 2006, British journal of pharmacology.

[43]  P. Robledo,et al.  Advances in the field of cannabinoid–opioid cross‐talk , 2008, Addiction biology.

[44]  R. Anton.  Naltrexone for the management of alcohol dependence. , 2008, The New England journal of medicine.

[45]  Some physical characteristics of NIDA marijuana cigarettes. , 1989, Addictive behaviors.

[46]  E. Nunes,et al.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial , 2011, The Lancet.

[47]  G. Bedi,et al.  Nabilone Decreases Marijuana Withdrawal and a Laboratory Measure of Marijuana Relapse , 2013, Neuropsychopharmacology.

[48]  D. Braida,et al.  Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system , 2001, Neuroscience.

[49]  R. Craft,et al.  THC−methadone and THC−naltrexone interactions on discrimination, antinociception, and locomotion in rats , 2011, Behavioural pharmacology.

[50]  J. Zacny,et al.  The role of human drug self-administration procedures in the development of medications. , 2008, Drug and alcohol dependence.

[51]  J. Hughes,et al.  Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. , 2007, Drug and alcohol dependence.